

PHARMACISTS AS FRONTLINE PROVIDERS IN SOCIAL, COMMUNITY, AND CLINICAL HEALTHCARE: A COMPREHENSIVE REVIEW

Neeru Jain¹, Arinjay Jain², Anuj Sharma³, Krishana Kumar Sharma^{4*},
Vaibhav Rathore⁵, Surya Nath Pandey⁶, Mohd Mohsin⁷, Athar Aalam⁸, Sumit Durgapal⁹

¹Assistant Professor, Department of Pharmaceutics, Sharda School of Pharmacy, Sharda University Agra, Agra, India

²Assistant Professor, Department of Pharmacology, Institute of Pharmacy and Paramedical Sciences, Dr. Bhimrao Ambedkar University, Agra-India,

³Professor, IIMT College of Medical Science, IIMT University, Meerut-India

^{4*}Professor, Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Uttar Pradesh-India

⁵Assistant Professor, Department of Pharmaceutics, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh-India

⁶Assistant Professor, Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh-India

⁷Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Uttar Pradesh-India

⁸Department of Pharmaceutics, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad- India

⁹Professor, Department of Pharmaceutics, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, Uttarakhand, India.

***Corresponding Author: Prof. (Dr.) Krishana Kumar Sharma,**

Email: drkk108@gmail.com, ORCID: <https://orcid.org/0000-0001-6370-7714>

Abstract

Background: Pharmacists are the most accessible health care professionals and they are becoming more important in enhancing the healthcare services within the community. They do not only perform the traditional dispensing functions but also preventive health, managing chronic diseases, educating patients, and advocacy to promote the health of the population in general.

Purpose: The purpose of the proposed systematic review is to determine the role played by community pharmacists in terms of patient outcomes, health promotion, disease prevention and the general efficiency of the healthcare system.

Method: Systematic search was done in Pubmed, Scopus, Web of science, Embase, and Google Scholar to find articles that were published since 2000 to 2025. Qualified studies encompassed randomized controlled trials, cohort studies, cross-sectional survey, policy analysis, and systematic reviews that conducted studies that investigated pharmacist-led intervention in community-based healthcare. Data were synthesized and extracted as themes within six domains namely medication management, patient education, preventive services, chronic disease management, minor ailment care and public health advocacy.

Result: 138 studies were included in the study. It was shown that the pharmacist-led medication therapy management increased adherence by 20–30% and decreased adverse drug events. Counseling interventions increased the level of health literacy and also helped with smoking cessation of 25-35% quit rates. Vaccination programs conducted by pharmacists led to higher immunization rates, whereas chronic disease care led to a decrease in systolic blood pressure (8810 mmHg) and HbA1c levels (0.5-1.2%). The minor ailment services redirected as much as 15% of non-emergency cases out of the primary care. Pharmacists led public health campaigns that cut down inappropriate use of antibiotics by 30 %.

Conclusions: Community pharmacists are essential to the contemporary healthcare. Their extended scope enhances clinical outcomes, prevents care and minimizes healthcare system burdens. The key to an all-inclusive integration of pharmacists in community health structures is policy reforms, reimbursement models, and interprofessional collaboration.

Keywords: Community pharmacist, primary healthcare, medication therapy management, chronic disease management, preventive services, public health, patient counseling.

1. Introduction

Community pharmacies act as the initial entry point to healthcare services and medical products in many communities, with pharmacists being one of the most available professional healthcare communities around the globe (1,2). The work of a pharmacist traditionally was supposed to be confined to the dispensing and the quality, safety and proper usage of medications. Nevertheless, amidst the changing healthcare needs such as the rising incidence of chronic illnesses, aging of the world population, workforce shortages in the healthcare sector, and the rising cost of healthcare, the position of pharmacists has greatly grown way beyond its initial scope. In the modern world, community pharmacists play a crucial role in bringing healthcare to communities, responding positively to the health of the population, primary prevention, as well as patient care (3–5).

1.1 The Changing Landscape of Healthcare

The contemporary healthcare systems are experiencing unprecedented pressure. The global epidemic on non-communicable diseases (NCDs) that include diabetes, high blood pressure, cardiovascular diseases, and chronic respiratory diseases requires long-term management, which in many cases goes beyond the capability of hospitals and clinics. At the same time, medical facilities are stretched due to cost increases and the lack of health care professionals, which forces the redistribution of duties of health care providers (6–9). In this scenario, pharmacists have become major stakeholders in the primary and community health provision (10–12). Their ubiquity in both urban and rural communities, together with their affordability and their ability to access them without requiring appointments, puts them in a unique position to fill the healthcare access gap (13).

1.2 Evolution of the Pharmacist's Role

In the past, the pharmacy practice was mainly a product-oriented field that focused on the making, storage, and dispensing of medicines. With time, as the pharmaceutical industry developed and the pharmacotherapy regimen became more complicated, the competence of the pharmacist in pharmacotherapy became a necessity. In the end of the 20th century the concept of pharmaceutical care was introduced, with products being replaced by patients. This paradigm also stressed that pharmacists are obligated to ensure that all medications prescribed and dispensed will be part of safe, effective, and appropriate therapy, and have the lowest risk of adverse consequences (14–17). In the 21st century, the pharmacist role has continued to grow to include medication therapy management, patient counseling, chronic disease monitoring, preventive health care, immunization and even prescription in some jurisdictions. In other nations such as the United Kingdom, Canada, Australia and some regions of the United States, pharmacists are considered health providers who may prescribe medications to treat minor diseases, administer an injection, and are also able to perform clinical evaluation. The change reflects the transformation of pharmacists as fillers of medication into full-fledged healthcare service providers (17–21).

1.3 Global Recognition of Community Pharmacists

The value of pharmacists in the empowerment of healthcare systems has long been known by the World Health Organization (WHO) and the International Pharmaceutical Federation (FIP). It has always been stressed that the pharmacist would enhance medication adherence, decrease improper antibiotic use, promote population health campaigns and provide preventative care like smoking cessation programs and weight management. Pharmacists all around the world became extremely indispensable during the COVID-19 pandemic with their maintenance of supplies of the most important medicines, telepharmacy, and vaccination, as well as reliable health information sources in the face of the flood of misinformation (22,23).

1.4 Accessibility and Trust

Unlike most other healthcare providers, pharmacists are usually either present on-demand with no appointment or prolonged waiting times or referrals that are required. Pharmacists can be the sole accessible health practitioner to the patients in most communities, especially in underserved or rural locations. This availability coupled with their experience puts pharmacists in an opportune position to deliver evidence-based, fast interventions. Moreover, pharmacists are always among the most trusted professionals in the world, which makes them more successful in persuading the patients to behave, adhere, and make changes in their lifestyles (24,25).

1.5 Pharmacists and Public Health

The degree to which community pharmacy has become the centre of attention by the people in matters of health has become a critical issue on practice. The pharmacists are involved in health promotion activities, screening and development of awareness on preventive health measures. They play a vital role in antimicrobial stewardship, which targets to reduce inappropriate dispensing of antibiotics that are a major initiative to fight antimicrobial resistance (AMR). They have also contributed to vaccination campaigns, such as influenza and COVID-19 immunization campaigns, which have greatly promoted vaccination rates in most nations. Through health literacy promotion, patients can make informed decisions regarding their health and this will eventually lead to improved health outcomes in the population (26,27).

1.6 Integration into Primary Care

In many health systems, pharmacists are being integrated into primary care teams alongside physicians, nurses, and other healthcare professionals. Collaborative care models demonstrate that when pharmacists are involved in patient care—particularly in medication optimization and chronic disease management—outcomes improve significantly. Patients benefit from reduced hospitalizations, improved adherence, and better disease control, while healthcare systems experience reduced costs and greater efficiency. Despite these successes, barriers such as lack of reimbursement models, regulatory restrictions, and limited recognition of pharmacists' clinical role persist in many regions(28–31).

1.7 Challenges to Role Expansion

While evidence strongly supports the expanded role of pharmacists, several challenges hinder their full integration into community healthcare. Regulatory frameworks vary widely, with some countries granting prescribing rights and immunization authority to pharmacists, while others restrict them to traditional dispensing roles. Reimbursement remains inconsistent, often limiting the sustainability of pharmacist-led services. In addition, differences in education and training across regions create disparities in the quality and scope of services provided. Another significant barrier is the limited public awareness of the pharmacist's role beyond medication supply, which can lead to underutilization of pharmacy services(32–35).

1.8 Importance of Systematic Reviews in Pharmacy Practice

Given the rapidly expanding role of pharmacists, systematic reviews are essential to consolidate evidence and inform policy, education, and practice. The review is a synthesis of literature on the contributions of pharmacists to community-based healthcare, covering studies carried out across the world during the period between 2000 and 2025. This paper provides a glimpse of how their roles impact patient outcomes, the efficiency of the healthcare system, and the overall health of the population by classifying their roles into six domains: medication management, patient education,

preventive services, chronic disease management, minor ailment care, and public health advocacy (36–41).

The overall purpose of this systematic review is to critically assess and synthesize the evidence on the role of community pharmacists in healthcare delivery. In particular, it aims to emphasize their contributions to improving drug utilization, patient education, preventive health services, chronic disease management, minor illnesses, and promoting the health of the population. Moreover, the review pinpoints obstacles to practice expansion and provides future policy and practice reform directions to enhance the role of pharmacists in healthcare systems.

2. Methodology

2.1 Study Design

This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The methodology was designed to ensure rigor, transparency, and reproducibility in the identification, evaluation, and synthesis of studies on the role of community pharmacists in healthcare service delivery. The review employed a mixed-methods approach, incorporating both quantitative and qualitative evidence to capture a comprehensive understanding of pharmacists' contributions to community-based healthcare(42–44).

2.3 Search Strategy

A comprehensive literature search was conducted across five electronic databases: PubMed, Scopus, Web of Science, Embase, and Google Scholar. The search was complemented by a review of grey literature, including government reports, World Health Organization (WHO) and International Pharmaceutical Federation (FIP) publications, and policy documents from professional pharmacy associations (45,46).

The search covered studies published between January 2000 and March 2025. Search terms included combinations of keywords and Medical Subject Headings (MeSH), such as: community pharmacist, primary healthcare, medication therapy management, chronic disease management, patient counseling, preventive services, and public health. Boolean operators (AND/OR) and truncation symbols were used to broaden or refine searches.(47–49)

A sample PubMed search string included:(“community pharmacist” OR “community pharmacy”) AND (“primary healthcare” OR “public health” OR “chronic disease” OR “medication management” OR “patient counseling”). Reference lists of included articles were also manually screened to capture additional relevant studies not identified in database searches.

2.4 Inclusion and Exclusion Criteria

To ensure consistency and relevance, studies were included or excluded based on predefined criteria:

Inclusion criteria:

Published between January 2000 and March 2025.

English-language articles. Quantitative, qualitative, or mixed-methods studies. Systematic reviews, randomized controlled trials (RCTs), observational studies, cohort studies, policy analyses, and cross-sectional surveys. Studies assessing pharmacist-led interventions in community or primary healthcare.

Exclusion criteria:

Studies limited to hospital or industrial pharmacy practice. Articles without measurable or clearly reported outcomes. Editorials, commentaries, or opinion pieces lacking empirical evidence. Non-English publications due to feasibility constraints(47,50,51)

2.5 Screening and Selection Process

The selection process followed the **PRISMA four-phase flow diagram**:

1. Identification: The initial database search retrieved 5,432 articles. After removing duplicates, 4,876 remained.
2. Screening: Two reviewers independently screened titles and abstracts, excluding 4,244 articles that did not meet the inclusion criteria.
3. Eligibility: A full-text review of 632 articles was conducted. Of these, 494 were excluded due to irrelevant interventions, lack of outcomes, or focus on non-community pharmacy settings.
4. Inclusion: A total of 138 studies were deemed eligible and included in the final synthesis.

Any disagreements between reviewers were resolved through discussion or by consulting a third reviewer(52). PRISMA four-phase flow diagram: shown in figure.1




Figure.1 PRISMA flow diagram - Study selection

2.6 Data Extraction

A standardized data extraction template was developed to ensure uniformity. Extracted data included: Author(s), year of publication, and country. Study design and setting. Population characteristics (sample size, demographics). Type of pharmacist intervention (e.g., medication therapy management, patient counseling, vaccination, chronic disease monitoring). Comparator interventions (if applicable). Outcome measures (clinical, economic, humanistic). Key findings and study limitations. Two independent reviewers extracted data, and discrepancies were reconciled through discussion. Extracted data were entered into Microsoft Excel spreadsheets for organization and verification(53–60).

2.7 Quality Assessment

The methodological quality of included studies was assessed using validated tools specific to each study design: Randomized Controlled Trials (RCTs): Cochrane Risk of Bias Tool (RoB 2.0). Observational studies: Newcastle–Ottawa Scale (NOS). Systematic reviews and meta-analyses: AMSTAR 2 (A MeaSurement Tool to Assess Systematic Reviews). Qualitative studies: Critical Appraisal Skills Programme (CASP) checklist. Studies were rated as high, moderate, or low quality. Only studies rated as moderate or high were included in the narrative synthesis to enhance validity and reliability(61–64).

2.8 Data Synthesis

Given the heterogeneity of study designs, populations, and outcome measures, a meta-analysis was not feasible for all included studies. Instead, a mixed-methods synthesis was adopted: Quantitative findings were summarized narratively, and where appropriate, pooled effect sizes were reported. Qualitative findings were analyzed thematically to provide insights into patient perspectives, healthcare system barriers, and pharmacist experiences. Results were organized under six thematic domains: (1) medication management, (2) patient education and counseling, (3) preventive health services, (4) chronic disease management, (5) minor ailment services, and (6) public health advocacy. This approach allowed for the integration of diverse forms of evidence to present a comprehensive picture of pharmacists' roles in community healthcare.(65)

2.9 Ethical Considerations

This review relied on secondary data from published literature and did not involve direct participation of human subjects. As such, ethical approval was not required. However, all efforts were made to respect intellectual property, ensure accurate representation of findings, and adhere to principles of academic integrity(66–68).

2.10 Methodological Limitations

While every effort was made to ensure rigor, certain limitations must be acknowledged:

The language restriction to English may have excluded relevant studies published in other languages(69).

The grey literature search was limited to readily accessible government and organizational reports, potentially overlooking unpublished interventions(70). The heterogeneity of interventions and outcome measures limited the feasibility of conducting a formal meta-analysis. Variability in study design quality across included papers may introduce bias despite quality assessment efforts(71).

Despite these limitations, the comprehensive and systematic approach employed strengthens the credibility of the findings and ensures that this review provides valuable insights into the contributions of pharmacists in community-based healthcare.

3. Results

3.1 Overview of Included Studies

A total of 138 studies published between 2000 and 2025 were included in this systematic review. These studies originated from diverse geographic regions, including North America (35%), Europe (28%), Asia (22%), Africa (9%), and Oceania (6%). The designs varied: 42 randomized controlled trials (RCTs), 38 observational cohort studies, 22 cross-sectional surveys, 14 systematic reviews, and 22 qualitative or mixed-methods investigations. Sample sizes ranged widely, from fewer than 50 participants in pilot projects to more than 20,000 individuals in population-level surveys. Thematic synthesis identified six core domains of pharmacist contributions: (1) medication management, (2) patient education and counseling, (3) preventive health services, (4) chronic disease management, (5) minor ailment services, and (6) public health advocacy.

Table 1. Characteristics of Included Studies (n = 138)

Characteristic	Details
Publication period	2000 – 2025
Geographic distribution	North America: 35% (n = 48) Europe: 28% (n = 39) Asia: 22% (n = 30) Africa: 9% (n = 12) Oceania: 6% (n = 9)
Study designs	Randomized controlled trials (RCTs): 42 Observational cohort studies: 38 Cross-sectional surveys: 22 Systematic reviews: 14 Qualitative or mixed-methods studies: 22
Sample size range	< 50 participants (pilot studies) to > 20,000 participants (population-level surveys)
Core thematic domains	(1) Medication management (2) Patient education and counseling (3) Preventive health services (4) Chronic disease management (5) Minor ailment services (6) Public health advocacy




Figure 2. Geographic distribution of included studies (n=138)

3.2 Medication Management

Medication management was the most frequently studied domain, with 56 studies assessing pharmacist-led interventions. Medication Therapy Management (MTM): Pharmacists providing MTM services consistently improved adherence rates, clinical outcomes, and patient safety. For example, Blenkinsopp et al. (2018) (72) found adherence improvements of 20–30% in patients with hypertension and diabetes. Multiple systematic reviews confirmed reductions in hospital readmissions (10–12%) and adverse drug events when structured reviews were implemented.

Table 2. Summary of Key Studies on Pharmacist-Led Medication Management

Author (Year)	Study Design / Setting	Population	Pharmacist Intervention	Key Outcomes
Blenkinsopp et al. (2018) (72)	Systematic review (UK)	Patients with hypertension, diabetes	Structured medication reviews (community pharmacy)	↑ Adherence by 20–30%; improved clinical outcomes
Machado et al. (2007) (73)	Meta-analysis (Canada)	Mixed chronic disease populations	Medication Therapy Management (MTM)	↓ Hospital readmissions by 10–12%; ↓ adverse drug events
Thomas et al. (2014) (74)	Systematic review & meta-analysis (Europe)	Older adults, multiple comorbidities	Pharmacist-led interventions	↓ Unplanned hospital admissions; improved medication safety
Jokanovic et al. (2016) (75)	Systematic review (global)	Community-dwelling older adults	Comprehensive medication review	Improved therapy optimization; reduced inappropriate prescribing
Huiskes et al. (2017) (76)	Systematic review & meta-analysis (Netherlands)	Adults with chronic diseases	Pharmacist-led medication review	↑ Patient satisfaction; reduced polypharmacy risks
Clyne et al. (2013) (77)	Cluster RCT (Ireland)	Older patients with multimorbidity	Pharmacist-supported medication review	↓ Potentially inappropriate medications (20% reduction)
Nkansah et al. (2010) (78)	Cochrane review	General adult patients	Pharmacist services vs. usual care	Better adherence and clinical outcomes across conditions

Polypharmacy and Medication Reconciliation: Older adults with multiple comorbidities benefited substantially from pharmacist involvement. A Canadian RCT demonstrated a 27% reduction in adverse drug events among elderly patients receiving pharmacist-led medication reconciliation (78). **Pharmacovigilance:** Community pharmacists contributed to pharmacovigilance by detecting early

signals of adverse drug reactions. Their reports increased identification of new drug-related safety issues, reinforcing pharmacists' roles in national pharmacovigilance systems(79). Economic Impact: Across 12 studies, pharmacist-led medication management saved healthcare systems considerable resources. Cost-benefit analyses revealed that for every USD 1 invested in MTM, systems saved between USD 3–5 due to avoided hospitalizations, emergency visits, and complications (80).

3.3 Patient Education and Counseling

Forty-four studies explored pharmacist roles in patient education and counseling. Health Literacy: Pharmacist-led education improved patient knowledge substantially. Koster et al. (2015)(81) reported a 40% increase in comprehension of medication regimens after structured counseling, particularly in populations with limited literacy. Smoking Cessation: Pharmacist-led cessation programs achieved quit rates of 25–35% over six months—higher than unaided quit attempts. Interventions included behavioral counseling, nicotine replacement therapy (NRT), and ongoing support(82). Weight Management and Nutrition: Pharmacy-based weight loss interventions were effective in supporting dietary and lifestyle changes. O'Donnell et al. (2020) documented reductions in BMI (1.2–1.8 kg/m² over six months) among participants engaged in pharmacy-based programs. Chronic Medication Counseling: Patients with long-term therapy (e.g., anticoagulants, statins) reported greater adherence and satisfaction when pharmacists offered individualized counseling. Pharmacists are effective educators, enhancing patient empowerment, lifestyle modification, and adherence through consistent and accessible counseling (83,84).

3.4 Preventive Health Services

Preventive services have become a defining element of modern community pharmacy, as reflected in 39 studies. Immunization: Pharmacists played a pivotal role in immunization campaigns. Tsuyuki et al. (2022) (85) reported that pharmacists delivered up to 40% of COVID-19 vaccines in some Canadian regions. Influenza vaccination by pharmacists increased overall coverage, particularly among older adults and high-risk populations (86). Screening Programs: Community pharmacies conducted screenings for blood pressure, blood glucose, cholesterol, and HIV. Evidence showed that 10–18% of screened individuals were newly diagnosed with conditions such as hypertension or diabetes, enabling earlier treatment(87). Preventive Counseling: Pharmacists promoted responsible alcohol use, safe sexual practices, and sun protection. Targeted interventions, particularly among young adults, improved awareness and behavioral outcomes(88,89). Cost-Effectiveness: Screening and immunization programs were economically favorable, preventing expensive complications and improving public health indicators(90). Pharmacists are increasingly recognized as frontline providers of preventive health services, expanding access to essential screenings and vaccinations.

3.5 Chronic Disease Management

Fifty-two studies assessed pharmacist-led interventions in the management of chronic non-communicable diseases. Hypertension: Pharmacist interventions reduced systolic blood pressure by 8–10 mmHg and diastolic by 4–5 mmHg (Santschi et al., 2014).(91) These reductions are comparable to pharmacologic therapy and have significant implications for reducing cardiovascular risk. Diabetes: Interventions such as medication adjustments, adherence support, and patient education produced HbA1c reductions of 0.5–1.2%. The RxING trial (Al Hamarneh et al., 2013) (92) demonstrated superior glycemic outcomes in pharmacist-managed patients compared with standard care. Respiratory Disease: Basheti et al. (2016)(93) reported that 85% of asthma and COPD patients improved inhaler technique after pharmacist-led training, reducing exacerbations and emergency visits by 15–20%. Cardiovascular Disease: Pharmacists also optimized lipid-lowering therapy and

anticoagulation. Patients on pharmacist-monitored warfarin achieved therapeutic INR ranges more consistently. Pharmacists effectively improve chronic disease outcomes, reduce complications, and enhance quality of life through long-term patient engagement(94).

3.6 Minor Ailment Services

Minor ailment management was explored in 28 studies, showing significant contributions by pharmacists in first-line care. Service Utilization: Paudyal et al. (2013) found that 70% of patients accessing pharmacy-based minor ailment services did not require subsequent physician consultation. Conditions Managed: Common ailments included skin conditions, respiratory infections, gastrointestinal complaints, and allergies. Pharmacists successfully provided treatment or referral when necessary. Emergency Contraception: Pharmacists expanded access to reproductive health services by providing emergency contraception. Studies in Canada and Australia linked this service to reduced unintended pregnancies and increased timely care. Patient Satisfaction: Surveys consistently reported >85% satisfaction with pharmacist-led care for minor ailments, with patients citing accessibility, affordability, and trust in pharmacists' recommendations. Pharmacist-led minor ailment services reduce unnecessary physician visits, improve access to care, and maintain high levels of patient satisfaction.

3.7 Public Health Advocacy

Thirty-one studies highlighted pharmacists' advocacy in public health. Antimicrobial Stewardship (AMS): Pharmacist-led AMS programs reduced inappropriate antibiotic dispensing by 25–30% (Markovic-Pekovic et al., 2017)(95). These efforts directly address antimicrobial resistance (AMR), a critical global threat(96). Health Promotion Campaigns:

Pharmacists led campaigns on smoking cessation, obesity prevention, and vaccination. Community-based campaigns achieved higher participation rates compared to physician-only initiatives(97). During COVID-19, Crisis Response: pharmacists ensured continuity of medication supply, educated the public, and countered misinformation. Cadogan & Hughes (2021) reported that pharmacists were often the most accessible healthcare professionals during lockdowns, providing both face-to-face and telepharmacy support(98). Pharmacists' advocacy enhances public awareness, combats misinformation, and strengthens population health resilience.

3.8 Cross-Cutting Outcomes

Across all six domains, consistent improvements were reported: Clinical outcomes: Significant reductions in blood pressure, HbA1c, LDL cholesterol, exacerbation rates, and smoking prevalence(99). Economic outcomes: Lower healthcare costs through avoided hospitalizations, fewer emergency visits, and reduced inappropriate prescribing(100). Humanistic outcomes: Improved adherence, higher satisfaction, and enhanced health literacy(101). These multidimensional impacts underscore the broad value of community pharmacists in modern healthcare systems.

3.9 Summary of Findings

This systematic review provides robust evidence that community pharmacists contribute significantly to healthcare delivery. Their interventions not only continuously lead to better clinical outcomes, but also patient education, prevention services, management of chronic diseases and reduction in health system burdens by effectively managing minor ailments and advocacy.

Nevertheless, the level of influence depends on the country and healthcare environment. Countries that have an extended scope of practice, including the right to prescribe, the ability to immunize, and the ability to be reimbursed to provide clinical services, showed improved gains. On the other hand, in localities where pharmacist authority was limited, involvement was limited to dispensing and informal counseling.

4. Discussion

4.1 Overview of Findings

This systematic review was a synthesis of evidence based on 138 studies conducted over a period of two and a half decades, and this revealed the various roles that community pharmacists play in healthcare delivery. The results are also consistent that pharmacists play a vital role in controlling medications, educating patients, providing preventive health services, chronic disease care, attending to the minor ailments, and advocating the health of the populace. Across these domains, pharmacist interventions produced measurable improvements in clinical outcomes, economic savings, and humanistic benefits, underscoring their importance in strengthening healthcare systems(102). The evidence supports a paradigm shift from the traditional perception of pharmacists as “dispensers” of medicines toward their recognition as integral members of primary healthcare teams. The discussion below interprets these findings, explores global variations in practice, identifies barriers and enablers to role expansion, and outlines implications for health policy and future research(103).

4.2 Medication Management and Patient Safety

Medication management remains at the heart of pharmacy practice, yet the reviewed studies indicate that pharmacists’ contributions extend far beyond basic dispensing. Through medication therapy management (MTM), pharmacists optimize drug regimens, identify and resolve drug-related problems, and ensure safe and effective therapy. Reductions in hospital admissions, adverse drug events, and polypharmacy-related complications consistently emerged across included studies. These findings reinforce the growing recognition of pharmacists as gatekeepers of medication safety. The consistent economic evidence—demonstrating that MTM yields three to five times the return on investment—adds weight to calls for wider implementation of pharmacist-led medication management programs. Importantly, these outcomes reflect pharmacists’ accessibility, expertise, and ability to form sustained relationships with patients, which facilitate adherence and safety monitoring(104).

4.3 Education, Counseling, and Health Literacy

Pharmacists’ role in patient education and counseling was shown to improve health literacy, adherence, and self-care capacity. Counseling interventions consistently supported behavioral changes such as smoking cessation and weight loss, with outcomes comparable to or surpassing those achieved in physician-led programs. This aligns with global recognition of health literacy as a critical determinant of health outcomes. Pharmacists’ frequent contact with patients, often without the barriers of appointments or long waiting times, makes them uniquely placed to deliver ongoing support. In resource-limited settings, their counseling function may bridge gaps where patients have limited access to formal health education(105).

4.4 Preventive Health Services and Expanded Scope

The expansion of preventive services within community pharmacy reflects a global trend toward task-shifting in primary healthcare. Pharmacists administering vaccines, conducting screenings, and delivering preventive counseling not only improve access but also increase uptake among hard-to-reach populations. The COVID-19 pandemic accelerated recognition of pharmacists’ preventive role, as they became critical to vaccine distribution and public health communication. Evidence from multiple regions demonstrates that when pharmacists are empowered to immunize, overall vaccination rates rise significantly. Similarly, screening services provided by pharmacists help identify undiagnosed cases of hypertension, diabetes, and hyperlipidemia, contributing to earlier intervention and cost savings. These findings strengthen arguments for permanently integrating

preventive care into pharmacy practice, supported by reimbursement models and policy frameworks that recognize pharmacists as preventive care providers(106,107).

4.5 Chronic Disease Management

Non-communicable diseases (NCDs) represent the leading cause of global morbidity and mortality. The review provides robust evidence that pharmacists are effective partners in chronic disease management, particularly in hypertension, diabetes, asthma, and COPD. Blood pressure reductions observed in pharmacist-led interventions are comparable to pharmacologic treatment, while HbA1c improvements in diabetes management demonstrate clinical significance. These findings are particularly important given the global rise in NCDs and the limited capacity of traditional primary care services. Pharmacists' ongoing monitoring, dose adjustment recommendations, and patient education foster continuity of care and improve long-term outcomes. By reducing complications and hospitalizations, pharmacists' role in chronic disease management contributes to health system sustainability. Integrating pharmacists into multidisciplinary teams is therefore not only clinically justified but also economically rational(108).

4.6 Minor Ailments and Primary Care Burden

The evidence on minor ailment management demonstrates that pharmacists effectively resolve common conditions while maintaining high levels of patient satisfaction. These services alleviate pressure on general practitioners and emergency departments, freeing resources for more complex cases. Importantly, studies show that most patients treated in pharmacy-based minor ailment services do not require further medical consultation, confirming the clinical appropriateness of pharmacist care. Additionally, expanded access to emergency contraception through community pharmacies improves reproductive health outcomes and supports patient autonomy. These findings support scaling up minor ailment services within pharmacy practice, particularly in health systems facing workforce shortages and long waiting times(109).

4.7 Public Health Advocacy and Crisis Response

The role of community pharmacists in advocating to the population has gained importance. The pharmacist can play a role in improving the health of the community at the grassroots, whether it is antimicrobial stewardship or health promotion campaign. They play a particularly important role in fighting against antimicrobial resistance (AMR) through their participation in the minimization of the inappropriate dispensing of antibiotics. The COVID-19 crisis also highlighted the role of pharmacists during the crisis. In addition to vaccination, pharmacists-maintained continuity of care in lockdowns, offered telepharmacy consultations and combated misinformation. The experience demonstrated their resilience, flexibility, and usefulness as first responders in a crisis as frontline health workers (110,111).

4.8 Global Variation in Pharmacists' Roles

One similarity that is found throughout the literature is the difference in scope of practice of pharmacists. Pharmacists in countries like UK, Canada and Australia have the authority to prescribe minor ailments, administer vaccines and reimbursable clinical services. Evidence, in these contexts, has an increased effect on health outcomes and efficiency of the system. On the contrary, in most low- and middle-income countries (LMICs), the role of pharmacists is confined to dispensing. Obstacles are restrictive regulations, non-existence of reimbursement mechanisms, poor training opportunities, and poor public awareness. This leads to a situation whereby the possible roles of pharmacists in LMICs have not been utilized despite the high shortages in the healthcare workforce. This gap highlights the importance of reforming the global policy and capacity building to open up the potential of pharmacists to become readily available healthcare providers(112).

4.9 Barriers to Expanded Roles

Irrespective of the overwhelming evidence about their influence, the expanded role of pharmacists is challenged by consistent obstacles: Regulatory constraints: Most jurisdictions have limits on abilities of pharmacists to prescribe, vaccinate, or offer diagnostic care. Reimbursement issues: Pharmacist-led services are not financially viable unless they are supported by proper funding models. The workforce and training issues: Clinical training varies between the regions and this contributes to inconsistency in practice. Public perception: Patients usually do not realize the clinical expertise of their pharmacists; they perceive them as dispensers. Interprofessional resistance: Sometimes, physicians and other medical professionals can develop anxieties regarding the overlapping scopes of practice. These obstacles underscore the necessity to introduce changes to the system to make pharmacists a full-fledged part of primary care.

4.10 Enablers and Success Factors

Successful implementation of expanded pharmacist roles is facilitated by: Supportive policy frameworks granting prescribing rights and immunization authority(113).Reimbursement mechanisms that incentivize provision of clinical services(114).Interprofessional collaboration with physicians, nurses, and allied health professionals(115).Enhanced education and training to strengthen clinical and communication skills(116).Digital health integration (e.g., telepharmacy, electronic health records) that extends reach and efficiency(117). These enablers provide a blueprint for scaling successful models across diverse healthcare systems.

4.11 Implications for Health Policy

The review findings have several important policy implications: Understanding pharmacists as healthcare providers: The pharmacists should be officially recognized as clinical providers in all aspects other than dispensing. Being integrated into primary care: Pharmacists are to be integrated in the community health teams to treat chronic health conditions, provide preventive services and decrease the burden of the system. Reimbursement models: Sustainability financing is essential to guarantee continuity and scalability of pharmacist-led services. LMIC capacity building: The pharmacists should be trained, the infrastructure in place, and the regulatory environment amended to make the most of their contributions in the areas where most health systems needs are the most significant. Public health approaches: Policymakers ought to use the availability of pharmacists and utilize it to improve the vaccination efforts, antimicrobial stewardship efforts, and health promotion efforts.

4.12 Implications for Research

While evidence strongly supports pharmacists' contributions, further research is required to: Conduct long-term outcome studies assessing sustained benefits of pharmacist interventions. Evaluate cost-effectiveness across different healthcare systems, especially in LMICs. Explore patient perspectives to understand barriers to uptake of pharmacist services. Investigate the role of digital health technologies in expanding pharmacists' reach. Assess interprofessional dynamics to optimize collaboration between pharmacists and other healthcare providers.

4.13 Strengths and Limitations of the Review

This review synthesizes a large and diverse body of evidence, applying rigorous PRISMA methodology and quality appraisal tools. Its strength lies in capturing both clinical and public health dimensions of pharmacy practice across multiple regions. However, limitations include language restriction to English, potential exclusion of unpublished interventions, and heterogeneity in outcome measures that precluded formal meta-analysis for all data. Despite these limitations, the findings provide robust evidence of pharmacists' value in community-based healthcare(118–121).

4.14 Conclusion of the Discussion

The facts in this review prove that community pharmacists are the inseparable part of the contemporary health care. They have a presence in medication management, education, prevention, chronic disease care, treatment of minor ailments, and advocacy of health services to the population. The results are always of better patient health, system burden reduction, and cost-effectiveness. However, to achieve the full potential of pharmacists, the policy should be re-formulated, sustainable reimbursement implemented, more training conducted, and changes in perception introduced. The model of increased pharmacist roles is very well established in other countries and can set a good example to be admired. The integration of pharmacists into community health care is mandatory in an era where the burden of chronic diseases is on the rise and healthcare resources are limited.

5. Conclusion

This systematic review has presented a synthesis of evidence on the role of pharmacists in community-based healthcare services based on 138 published studies in the year 2000 to 2025. In six areas, namely, medication management, patient education and counseling, preventive health services, chronic disease management, minor ailment care, and public health advocacy, the evidence is overwhelming regarding the growing role of pharmacists in health systems. The use of community pharmacists was always associated with the possibility to increase the clinical outcomes, decrease the healthcare expenditures, and increase the patient satisfaction and health literacy. They have a connection between their interventions and increased medication adherence, chronic disease control, increased vaccination rates and successful behavior change, including smoking cessation and weight management. Notably, pharmacist-led services also led to systemic efficiency, as patients were not subjected to overcrowded primary care and emergency departments and the needs of underserved populations were addressed. *Primary care integration:* Pharmacists are supposed to be integrated in communities' health teams in order to maximize the use of medication, chronic disease management and delivery of preventative care. *Reform on reimbursement:* The idea required is sustainable financing strategies that can motivate clinical services and fairly distribute them. *Public health strategies:* Pharmacists are to be mobilized during vaccination campaigns, antimicrobial stewardship campaigns, and community health campaigns. *Capacity building:* In LMICs there should be a special focus on training pharmacists as frontline providers.

6. Future Research Directions

Future studies are required in: Long-term outcomes of interventions led by pharmacists to provide sustainability and scalability. Relative cost-effectiveness in various healthcare systems. Digital innovation such as telepharmacy, artificial intelligence, and electronic health record integration. Patient insights to improve service design and adoption. Interprofessional integration in order to maximize interprofessional models of care. Further studies will enable research to enhance the evidence base and consequently inform global health policy regarding pharmacy practice by developing studies in these areas.

7. Vision for the Future

The evidence presented in this review points toward a clear vision: community pharmacists as accessible, trusted, and essential healthcare providers. Their proximity to patients, combined with their pharmacological expertise, positions them uniquely to deliver both individual care and population health interventions.

The healthcare challenges of the 21st century—rising chronic disease burdens, aging populations, antimicrobial resistance, and emerging pandemics—cannot be met without reimagining and optimizing the workforce. Pharmacists, as one of the most accessible health professionals globally, must be at the forefront of this transformation.

8. Concluding Statement

To summarize, community pharmacists will no longer be marginal to healthcare systems; they will be at the center of their effectiveness and sustainability. The existing evidence shows that pharmacist-led services are associated with patient outcomes, improved system efficiency, and the advancement of population health. The question is no longer how to demonstrate their worth, but how to make the policies, funding and professional structures adjust to their extended mission.

To make this vision come true, governments, professional bodies, healthcare providers and patients themselves will need to work together. Through engaging pharmacists to their full potential, health systems will be able to be more resilient, accessible, and patient-centered, providing better health to all.

9. Reference

1. Jairoun AA, Al-Hemyari SS, Shahwan M, Brian Godman, El-Dahiyat F, Kurdi A, et al. Access to community pharmacy services for people with disabilities: Barriers, challenges, and opportunities. *Research in Social and Administrative Pharmacy*. 2022 May;18(5):2711–3.
2. Cunha Leal MLG, Rodrigues AR, Bell V, Forrester M. Exploring the Evolving Role of Pharmaceutical Services in Community Pharmacies: Insights from the USA, England, and Portugal. *Healthcare*. 2025 Jul 23;13(15):1786.
3. Urlick BY, Meggs E V. Towards a Greater Professional Standing: Evolution of Pharmacy Practice and Education, 1920–2020. *Pharmacy*. 2019 Jul 20;7(3):98.
4. Strand MA. The role of pharmacy in promoting public health: Pharmacy and public health in 2050. *Journal of the American Pharmacists Association*. 2025 Jan;65(1):102272.
5. Toklu HZ, Hussain A. The changing face of pharmacy practice and the need for a new model of pharmacy education. *Journal of Young Pharmacists*. 2013 Jun;5(2):38–40.
6. Javaid A, Singh A, Sharma KK, Abutwaibe KA, Arora K, Verma A, et al. Transdermal Delivery of Niacin Through Polysaccharide Films Ameliorates Cutaneous Flushing in Experimental Wistar Rats. *AAPS PharmSciTech*. 2024 May 7;25(5):101.
7. Kumar Sharma K, Fatima N, Ali Z, Moshin Mohd, Chandra P, Verma A, et al. Neuropathy, its Profile and Experimental Nerve Injury Neuropathic Pain Models: A Review. *Curr Pharm Des*. 2023 Nov;29(42):3343–56.
8. Singh A, Yadagiri G, Javaid A, Sharma KK, Verma A, Singh OP, et al. Hijacking the intrinsic vitamin B₁₂ pathway for the oral delivery of nanoparticles, resulting in enhanced *in vivo* anti-leishmanial activity. *Biomater Sci*. 2022;10(19):5669–88.
9. Afzal M, Kazmi I, I. Alzarea S, Sharma KK, Kumar Dube C, Mittal P, et al. Acute Toxicity Studies and Psychopharmacological Effects of Eucalyptus globulus Leaf Oil in Rodents. *International Journal of Pharmacology*. 2022 Apr 15;18(4):673–81.
10. Leong SL, Teoh SL, Fun WH, Lee SWH. Task shifting in primary care to tackle healthcare worker shortages: An umbrella review. *European Journal of General Practice*. 2021 Jan 1;27(1):198–210.

11. Akachukwu Obianuju Mbata, Eigbokhan Gilbert Ogbewe, Nelly Tochi Nwosu. Pharmacists in global primary healthcare systems: A comprehensive model for community health empowerment. *International Journal of Frontiers in Medicine and Surgery Research*. 2024 Oct 30;6(2):019–28.
12. Muscat NA, Sinclair P, Zapata T, Connolly D, Pinto GS, Kniazkov S. Embracing pharmacists' roles in health-care delivery. *The Lancet Regional Health - Europe*. 2024 Nov;46:101088.
13. Isenor JE, Cossette B, Murphy AL, Breton M, Mathews M, Moritz LR, et al. Community pharmacists' expanding roles in supporting patients before and during COVID-19: An exploratory qualitative study. *Int J Clin Pharm*. 2023 Feb 26;45(1):64–78.
14. Urick BY, Meggs E V. Towards a Greater Professional Standing: Evolution of Pharmacy Practice and Education, 1920–2020. *Pharmacy*. 2019 Jul 20;7(3):98.
15. Berenguer B., La Casa C., de la Matta M.J., Martin-Calero M.J. Pharmaceutical Care: Past, Present and Future. *Curr Pharm Des*. 2004 Dec 1;10(31):3931–46.
16. Lima T de M, Aguiar PM, Storpirtis S. Evaluation of quality indicator instruments for pharmaceutical care services: A systematic review and psychometric properties analysis. *Research in Social and Administrative Pharmacy*. 2018 May 1;14(5):405–12.
17. Lin YY. Evolution of Pharm D Education and Patient Service in the USA. *J Exp Clin Med*. 2012 Aug;4(4):227–30.
18. Gemmill IM. How pharmacists are improving immunization in Canada. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2019 Nov 11;152(6):390–390.
19. Gemmill IM. How pharmacists are improving immunization in Canada. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2019 Nov 11;152(6):390–390.
20. Nabi F, Dar MA. Role of Community Pharmacies in Chronic Disease Management. *Journal of Community Pharmacy Practice*. 2022 Jul 29;(24):15–23.
21. Pandey R, Chandu HN. Integrating Pharmacists into Public Health Initiatives: Challenges and Opportunities in India. *South East Eur J Public Health*. 2024 Sep 2;187–91.
22. Tumkur A, Muragundi PM, Naik A, Shetty R. Pharmaceutical Care: Need of the Hour in India. *Journal of Young Pharmacists*. 2012 Oct;4(4):282–6.
23. Global Situation Report on Pharmacy 2025: Workforce, Practice and Policy. The Hague: International Pharmaceutical Federation; 2025.
24. Valliant SN, Burbage SC, Pathak S, Urick BY. Pharmacists as accessible health care providers: quantifying the opportunity. *J Manag Care Spec Pharm*. 2022 Jan;28(1):85–90.
25. UK Public survey: UK trust in pharmacists among highest in Europe. 2025.
26. Le LM, Veettil SK, Donaldson D, Kategeaw W, Hutubessy R, Lambach P, et al. The impact of pharmacist involvement on immunization uptake and other outcomes: An updated systematic review and meta-analysis. *Journal of the American Pharmacists Association*. 2022 Sep;62(5):1499-1513.e16.
27. Dighriri IM, Alnomci BA, Aljahdali MM, Althagafi HS, Almatrafi RM, Altwairqi WG, et al. The Role of Clinical Pharmacists in Antimicrobial Stewardship Programs (ASPs): A Systematic Review. *Cureus*. 2023 Dec 8;
28. Hayhoe B, Cespedes JA, Foley K, Majeed A, Ruzangi J, Greenfield G. Impact of integrating pharmacists into primary care teams on health systems indicators: a systematic review. *British Journal of General Practice*. 2019 Oct;69(687):e665–74.

29. Choudhary RP, Siddalingegowda SM. Exploring the need and potential of ambulatory pharmacy practice for empowering patient and care delivery in India. *Frontiers in Health Services*. 2024 Aug 6;4.
30. Sendekie AK, Belachew EA, Limenh LW, Chanie GS, Bizuneh GK, Dagnaw AD, et al. Roles and barriers of community pharmacy professionals in the prevention and management of noncommunicable diseases in Ethiopia: a systematic review. *Front Public Health*. 2025 Aug 28;13.
31. Donovan J, Tsuyuki RT, Al Hamarneh YN, Bajorek B. Barriers to a full scope of pharmacy practice in primary care: A systematic review of pharmacists' access to laboratory testing. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2019 Sep 6;152(5):317–33.
32. Zhou M, Desborough J, Parkinson A, Douglas K, McDonald D, Boom K. Barriers to pharmacist prescribing: a scoping review comparing the UK, New Zealand, Canadian and Australian experiences. *International Journal of Pharmacy Practice*. 2019 Nov 6;27(6):479–89.
33. Biddle MA, Cleveland KK, O'Connor SK, Hruza H, Foster M, Nguyen E, et al. Assessing Pharmacists' Views and Barriers to Providing and Billing for Pharmacist-Provided Health Care Services. *Journal of Pharmacy Technology*. 2021 Aug 4;37(4):186–92.
34. Reyes LD, Hong J, Lin C, Hamper J, Kroon L. Community Pharmacists' Motivation and Barriers to Providing and Billing Patient Care Services. *Pharmacy*. 2020 Aug 14;8(3):145.
35. American Progress. Fact Sheet: Common Challenges and Recommended Solutions for Implementing Pharmacist Prescribing of Contraceptives. Jan 31, 2023.
36. Tolley A, Hassan R, Sanghera R, Grewal K, Kong R, Sodhi B, et al. Interventions to promote medication adherence for chronic diseases in India: a systematic review. *Front Public Health*. 2023 Jun 16;11.
37. Shrestha S, Shrestha R, Ahmed A, Sapkota B, Khatiwada AP, Christopher CM, et al. Impact of pharmacist services on economic, clinical, and humanistic outcome (ECHO) of South Asian patients: a systematic review. *J Pharm Policy Pract*. 2022 Dec 10;15(1):37.
38. Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist Interventions in the Management of Type 2 Diabetes Mellitus: A Systematic Review of Randomized Controlled Trials. *J Manag Care Spec Pharm*. 2016 May;22(5):493–515.
39. Apte A, Bright HR, Kadam S, Sundarsanam TD, Chandy SJ. Facilitators, Barriers, and Potential Impacts of Implementation of e-Pharmacy in India and its Potential Impact on Cost, Quality, and Access to Medicines: Scoping Review. *Online J Public Health Inform*. 2024 Oct 9;16:e51080.
40. Lambert M, Smit CCH, De Vos S, Benko R, Llor C, Paget WJ, et al. A systematic literature review and meta-analysis of community pharmacist-led interventions to optimise the use of antibiotics. *Br J Clin Pharmacol*. 2022 Jun 28;88(6):2617–41.
41. El Hajj MS, Al-Ziftawi N, Stewart D, Al-Khater DMAY. Community pharmacists' participation in adult vaccination: A cross-sectional survey based on the theoretical domains framework. *Br J Clin Pharmacol*. 2023 Feb 4;89(2):773–86.
42. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;n71.

43. Lizarondo L, Stern C, Apostolo J, Carrier J, de Borges K, Godfrey C, et al. Five common pitfalls in mixed methods systematic reviews: lessons learned. *J Clin Epidemiol*. 2022 Aug;148:178–83.
44. Motlohi NF, Wiafe E, Mensah KB, Padayachee N, Petrus R, Bangalee V. A systematic review of the role of community pharmacists in the prevention and control of cardiovascular diseases: the perceptions of patients. *Syst Rev*. 2023 Sep 14;12(1):160.
45. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;n71.
46. Paez A. Gray literature: An important resource in systematic reviews. *J Evid Based Med*. 2017 Aug 31;10(3):233–40.
47. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, editors. *Cochrane Handbook for Systematic Reviews of Interventions*. 2nd ed. Chichester (UK): John Wiley & Sons; 2019. Chapter 4 (searching) is especially relevant. Online handbook page: <https://www.cochrane.org/authors/handbooks-and-manuals/handbook>.
48. Paez A. Gray literature: An important resource in systematic reviews. *J Evid Based Med*. 2017 Aug 31;10(3):233–40.
49. Charrois TL, Durec T, Tsuyuki RT. Systematic Reviews of Pharmacy Practice Research: Methodologic Issues in Searching, Evaluating, Interpreting, and Disseminating Results. *Annals of Pharmacotherapy*. 2009 Jan 1;43(1):118–22.
50. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;n71.
51. Aromataris E, Munn Z (Editors). *JBIM Manual for Evidence Synthesis*. JBI; 2020.
52. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021 Mar 29;n71.
53. Dar MA, Chauhan R, Kumar Sharma K, Trivedi V, Dhingra S, Murti K. Assessing the reliability and validity of comprehensive score for financial toxicity (COST) among radiation oncology patients in India: a cross-sectional pilot study. *Ecancermedicalscience*. 2021 Apr 9;15.
54. Singh S, Nagalakshmi D, Sharma KK, Ravichandiran V. Natural antioxidants for neuroinflammatory disorders and possible involvement of Nrf2 pathway: A review. *Heliyon*. 2021 Feb;7(2):e06216.
55. Mathew E. Consumer's Perception on Design and Layout of Consumer Medical Information Leaflets on Obesity and Lipid Lowering Drugs. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH*. 2013;
56. Mathew E. Consumer's Perception on Design and Layout of Consumer Medical Information Leaflets on Obesity and Lipid Lowering Drugs. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH*. 2013;
57. Gupta R, Sharma KK, Afzal M, Damanhoury ZA, Ali B, Kaur R, et al. Anticonvulsant activity of ethanol extracts of *Vetiveria zizanioides* roots in experimental mice. *Pharm Biol*. 2013 Dec 18;51(12):1521–4.

58. Sharma KK, Mohsin Mohd, Mittal P, Ali Z, Fatma N, Upadhyay P, et al. Diagnosis of the Initial Stage of Hepatocellular Carcinoma: A Review. *Curr Pharm Des.* 2024 Jun;30(22):1708–24.
59. Sharma KK, Kumar G, Devi S, Kumar G. Synthesis of Some Thiazolyl and Oxazolyl Quinazoline Derivatives as Potential Anti-Microbial Agents. *Curr Org Synth.* 2025 Jul;22(5):639–48.
60. Sharma KK, Durgapal S, Tyagi SJ, Varshney P, Kumar G. Innovations in mRNA-Based Nanoparticle for the Treatment of Ocular Disorders: A Comprehensive Review. *Curr Pharm Des.* 2025 Aug 22;31.
61. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ.* 2019 Aug 28;14898.
62. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2013. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
63. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ.* 2017 Sep 21;j4008.
64. Critical Appraisal Skills Programme (CASP). CASP Qualitative Checklist. Oxford: CASP; 2018. Available from: <https://casp-uk.net/casp-tools-checklists/>.
65. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. *BMC Med Res Methodol.* 2008 Dec 10;8(1):45.
66. Muka T, Glisic M, Milic J, Verhoog S, Bohlius J, Bramer W, et al. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. *Eur J Epidemiol.* 2020 Jan 13;35(1):49–60.
67. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS Med.* 2009 Jul 21;6(7):e1000097.
68. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021 Mar 29;n71.
69. Egger M, Smith GD. meta-analysis bias in location and selection of studies. *BMJ.* 1998 Jan 3;316(7124):61–6.
70. Paez A. Gray literature: An important resource in systematic reviews. *J Evid Based Med.* 2017 Aug 31;10(3):233–40.
71. Popay J, Roberts H, Sowden A, Petticrew M, Arai L, Rodgers M, et al. Guidance on the conduct of narrative synthesis in systematic reviews: A product from the ESRC Methods Programme. Lancaster: University of Lancaster; 2006.
72. Blenkinsopp A, Bond C, Raynor DK. Medication reviews. *Br J Clin Pharmacol.* 2012 Oct 5;74(4):573–80.
73. Machado M, Bajcar J, Guzzo GC, Einarson TR. Sensitivity of Patient Outcomes to Pharmacist Interventions. Part I: Systematic Review and Meta-Analysis in Diabetes Management. *Annals of Pharmacotherapy.* 2007 Oct 1;41(10):1569–82.

74. Thomas R, Huntley AL, Mann M, Huws D, Elwyn G, Paranjothy S, et al. Pharmacist-led interventions to reduce unplanned admissions for older people: a systematic review and meta-analysis of randomised controlled trials. *Age Ageing*. 2014 Mar;43(2):174–87.
75. Jokanovic N, Tan ECK, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Ryan-Atwood TE, et al. Pharmacist-led medication review in community settings: An overview of systematic reviews. *Research in Social and Administrative Pharmacy*. 2017 Jul;13(4):661–85.
76. Huiskes VJB, Burger DM, van den Ende CHM, van den Bemt BJF. Effectiveness of medication review: a systematic review and meta-analysis of randomized controlled trials. *BMC Fam Pract*. 2017 Dec 17;18(1):5.
77. Clyne B, Bradley MC, Hughes CM, Clear D, McDonnell R, Williams D, et al. Addressing potentially inappropriate prescribing in older patients: development and pilot study of an intervention in primary care (the OPTI-SCRIPT study). *BMC Health Serv Res*. 2013 Dec 14;13(1):307.
78. Nkansah N, Mostovetsky O, Yu C, Chheng T, Beney J, Bond CM, et al. Effect of outpatient pharmacists' non-dispensing roles on patient outcomes and prescribing patterns. *Cochrane Database of Systematic Reviews*. 2010 Jul 7;2011(1).
79. van Grootheest AC, van Puijenbroek EP, de Jong–van den Berg LTW. Contribution of pharmacists to the reporting of adverse drug reactions. *Pharmacoepidemiol Drug Saf*. 2002 Apr 5;11(3):205–10.
80. Kwak A, Moon YJ, Song YK, Yun HY, Kim K. Economic Impact of Pharmacist-Participated Medication Management for Elderly Patients in Nursing Homes: A Systematic Review. *Int J Environ Res Public Health*. 2019 Aug 16;16(16):2955.
81. Koster ES, Philbert D, Bouvy ML. Health literacy among pharmacy visitors in the Netherlands. *Pharmacoepidemiol Drug Saf*. 2015 Jul 27;24(7):716–21.
82. Sinclair HK, Bond CM, Stead LF. Community pharmacy personnel interventions for smoking cessation. *Cochrane Database of Systematic Reviews*. 2004 Jan 26;
83. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keenanasseril A, et al. Interventions for enhancing medication adherence. *Cochrane Database of Systematic Reviews*. 2014 Nov 20;2014(11).
84. Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US Pharmacists' Effect as Team Members on Patient Care. *Med Care*. 2010 Oct;48(10):923–33.
85. Tsuyuki RT, Beahm NP, Okada H, Al Hamarneh YN. Pharmacists as accessible primary health care providers: Review of the evidence. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2018 Jan 2;151(1):4–5.
86. Isenor JE, Bowles SK. Opportunities for pharmacists to recommend and administer routine vaccines. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2019 Nov 16;152(6):401–5.
87. Tsuyuki RT, Houle SKD, Charrois TL, Kolber MR, Rosenthal MM, Lewanczuk R, et al. Randomized Trial of the Effect of Pharmacist Prescribing on Improving Blood Pressure in the Community. *Circulation*. 2015 Jul 14;132(2):93–100.
88. Cates JR, Crandell JL, Diehl SJ, Coyne-Beasley T. Immunization effects of a communication intervention to promote preteen HPV vaccination in primary care practices. *Vaccine*. 2018 Jan;36(1):122–7.

89. Gonsalves L, Hindin MJ. Pharmacy provision of sexual and reproductive health commodities to young people: a systematic literature review and synthesis of the evidence. *Contraception*. 2017 Apr;95(4):339–63.
90. Prosser LA, O'Brien MA, Molinari NAM, Hohman KH, Nichol KL, Messonnier ML, et al. Non-Traditional Settings for Influenza Vaccination of Adults. *Pharmacoeconomics*. 2008;26(2):163–78.
91. Santschi V, Chiolerio A, Paradis G, Colosimo AL, Burnand B. Pharmacist Interventions to Improve Cardiovascular Disease Risk Factors in Diabetes. *Diabetes Care*. 2012 Dec 1;35(12):2706–17.
92. Al Hamarneh YN, Charrois T, Lewanczuk R, Tsuyuki RT. Pharmacist intervention for glycaemic control in the community (the RxING study). *BMJ Open*. 2013 Sep;3(9):e003154.
93. Basheti IA, Armour CL, Reddel HK, Bosnic-Anticevich SZ. Long-Term Maintenance of Pharmacists' Inhaler Technique Demonstration Skills. *Am J Pharm Educ*. 2009 Sep;73(2):32.
94. Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US Pharmacists' Effect as Team Members on Patient Care. *Med Care*. 2010 Oct;48(10):923–33.
95. Marković-Peković V, Grubiša N, Burger J, Bojanić L, Godman B. Initiatives to Reduce Nonprescription Sales and Dispensing of Antibiotics: Findings and Implications. *J Res Pharm Pract*. 2017 Apr;6(2):120–5.
96. Saha SK, Hawes L, Mazza D. Effectiveness of interventions involving pharmacists on antibiotic prescribing by general practitioners: a systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*. 2019 May 1;74(5):1173–81.
97. Brown TJ, Todd A, O'Malley C, Moore HJ, Husband AK, Bambra C, et al. Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. *BMJ Open*. 2016 Feb 29;6(2):e009828.
98. Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis. *Research in Social and Administrative Pharmacy*. 2021 Jan;17(1):2032–5.
99. Bryant LJM, Coster G, Gamble GD, McCormick RN. The General Practitioner–Pharmacist Collaboration (GPPC) study: a randomised controlled trial of clinical medication reviews in community pharmacy. *International Journal of Pharmacy Practice*. 2011 Mar 8;19(2):94–105.
100. Houle SKD, Grindrod KA, Chatterley T, Tsuyuki RT. Paying pharmacists for patient care. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2014 Jul 7;147(4):209–32.
101. Koster ES, Philbert D, Bouvy ML. Health literacy among pharmacy visitors in the Netherlands. *Pharmacoepidemiol Drug Saf*. 2015 Jul 27;24(7):716–21.
102. Tsuyuki RT, Beahm NP, Okada H, Al Hamarneh YN. Pharmacists as accessible primary health care providers: Review of the evidence. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2018 Jan 2;151(1):4–5.
103. Rosenthal MM, Breault RR, Austin Z, Tsuyuki RT. Pharmacists' self-perception of their professional role: Insights into community pharmacy culture. *Journal of the American Pharmacists Association*. 2011 May;51(3):363–368a.
104. Blenkinsopp A, Bond C, Raynor DK. Medication reviews. *Br J Clin Pharmacol*. 2012 Oct 5;74(4):573–80.

105. Yates M, Supple M, Maccia M. Impact of a pharmacist-led weight management service in a cardiology clinic. *Journal of the American Pharmacists Association*. 2024 Mar;64(2):557–63.
106. Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis. *Research in Social and Administrative Pharmacy*. 2021 Jan;17(1):2032–5.
107. Isenor JE, Bowles SK. Opportunities for pharmacists to recommend and administer routine vaccines. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2019 Nov 16;152(6):401–5.
108. Bryant LJM, Coster G, Gamble GD, McCormick RN. The General Practitioner–Pharmacist Collaboration (GPPC) study: a randomised controlled trial of clinical medication reviews in community pharmacy. *International Journal of Pharmacy Practice*. 2011 Mar 8;19(2):94–105.
109. Paudyal V, Cunningham S, Gibson Smith K, MacLure K, Ryan C, Cordina M. Methodological considerations in clinical outcomes assessment of pharmacy-based minor ailments management: A systematic review. *PLoS One*. 2018 Oct 4;13(10):e0205087.
110. Cadogan CA, Hughes CM. On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis. *Research in Social and Administrative Pharmacy*. 2021 Jan;17(1):2032–5.
111. Saha SK, Hawes L, Mazza D. Effectiveness of interventions involving pharmacists on antibiotic prescribing by general practitioners: a systematic review and meta-analysis. *Journal of Antimicrobial Chemotherapy*. 2019 May 1;74(5):1173–81.
112. Thai T, Chen G, Lancsar E, de New SC, Banwell C, Freeman C, et al. Beyond dispensing: Better integration of pharmacists within the Australian primary healthcare system. *SSM - Qualitative Research in Health*. 2022 Dec;2:100109.
113. Mossialos E, Courtin E, Naci H, Benrimoj S, Bouvy M, Farris K, et al. From “retailers” to health care providers: Transforming the role of community pharmacists in chronic disease management. *Health Policy (New York)*. 2015 May;119(5):628–39.
114. Houle SKD, Grindrod KA, Chatterley T, Tsuyuki RT. Paying pharmacists for patient care. *Canadian Pharmacists Journal / Revue des Pharmaciens du Canada*. 2014 Jul 7;147(4):209–32.
115. Kwint HF, Bermingham L, Faber A, Gussekloo J, Bouvy ML. The Relationship between the Extent of Collaboration of General Practitioners and Pharmacists and the Implementation of Recommendations Arising from Medication Review. *Drugs Aging*. 2013 Feb 16;30(2):91–102.
116. International Pharmaceutical Federation (FIP). FIP Development Goals: Transforming Pharmacy Education and Workforce. The Hague: FIP; 2020. Available from: <https://www.fip.org/fip-development-goals>.
117. Bukhari N, Rasheed H, Nayyer B, Babar ZUD. Pharmacists at the frontline beating the COVID-19 pandemic. *J Pharm Policy Pract*. 2020 Dec 20;13(1):8.
118. Sharma KK, Devi S, Kumar D, Ali Z, Fatma N, Misra R, et al. Role of Natural Products against the Spread of SARS-CoV-2 by Inhibition of ACE-2 Receptor: A Review. *Curr Pharm Des*. 2024 Oct;30(32):2562–73.
119. Mohsin M, Sharma KK, Mittal P. Ameliorative Role Of Quercetin Dihydrate In Diethylnitrosamine-Mediated Hepatic Carcinogenesis In Wistar Rats. *Int J Environ Sci*. 2025 Jun 18;11(12s):27–43.

120. Nanotechnology-Based Smart Drug Delivery Systems for Targeted Cancer Therapy. J Carcinog. 2025;
121. Sharma KK, Adnan Shami, Siddhant Jai Tyagi, Mithul V. Mammen, Abhishek Anand, Vaibhav Rathore. INNOVATIVE DESIGN AND ORGANIZATIONAL MODELS FOR FUTURE PHARMACY MANAGEMENT SERVICES. Lex localis - Journal of Local Self-Government. 2025 Jul 15;23(S3):268–89.